We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI-Based Tool Uses Tumor Gene Sequencing Data to Identify Site of Origin for Enigmatic Cancers

By LabMedica International staff writers
Posted on 08 Aug 2023
Print article
Image: The AI model can help determine where a patient’s cancer arose (Photo courtesy of Freepik)
Image: The AI model can help determine where a patient’s cancer arose (Photo courtesy of Freepik)

For a small segment of cancer patients, the origin of their cancer remains undetermined, making it challenging to select the most effective treatment. This is because most cancer medications are designed for distinct types of cancer. Researchers have now developed a new methodology, utilizing machine learning, to pinpoint the origins of these elusive cancers. This computational model evaluates the sequences of roughly 400 genes to predict a tumor's site of origin. In a dataset comprising about 900 patients, the model was able to accurately categorize 40% of untraceable tumors, thus potentially increasing the number of patients eligible for genomically guided, targeted treatment by 2.2 times.

In 3 to 5% of cancer cases, especially when tumors have metastasized across the body, determining the initial site where the cancer originated is a challenge. These tumors are termed as cancers of unknown primary (CUP). The inability to determine their origin hampers the administration of "precision" drugs, which are tailored for specific cancer types. These precision medications are not only more effective but also have fewer side effects than the more general treatments often prescribed to CUP patients. To address this issue, researchers from the Massachusetts Institute of Technology (MIT, Cambridge, MA, USA) and Dana-Farber Cancer Institute (Boston, MA, USA) analyzed routinely collected genetic data from Dana-Farber to predict cancer types. This data consisted of gene sequences for about 400 genes that are frequently mutated in cancer cases. Using this data, a machine-learning model was trained on nearly 30,000 patients diagnosed with one of 22 known cancer types.

When this model, termed OncoNPC, was tested on 7,000 tumors that it had never seen before but whose site of origin was known, it predicted their origins with an astounding 80% accuracy, which increased to 95% for tumors with high-confidence predictions which constituted about 65% of the total. This model was then applied to around 900 CUP tumors from Dana-Farber. For 40% of these tumors, the model delivered high-confidence origin predictions. Further, when the model's forecasts were corroborated against germline (inherited) mutations in some tumors with available data, the team found that the model’s predictions often matched the type of cancer most strongly predicted by the germline mutations than any other type of cancer.

The model's accuracy was further validated by comparing CUP patients' survival time against the typical prognosis for the type of cancer predicted by the model. For instance, CUP patients predicted to have a grimmer prognosis, like pancreatic cancer, indeed had comparatively shorter survival times, while those predicted to have a more favorable prognosis, such as neuroendocrine tumors, lived longer. Additionally, 10% of the studied CUP patients received a targeted treatment based on oncological speculation. Among these, those treated in line with the model's predictions had better outcomes. The researchers also examined if the model’s predictions could be useful based on the types of treatments that CUP patients analyzed in the study had received. Around 10% of these patients had received targeted treatment, based on their oncologists’ best guess about where their cancer had originated. Among these patients, those who received treatment consistent with the type of cancer predicted by the model for them fared better than patients who received a treatment generally administered for a different type of cancer than what the model predicted for them.

Furthermore, the researchers used the model to identify an additional 15% of patients (a 2.2-fold increase) who could have benefited from targeted treatments if their cancer's origin had been known. Sadly, they were treated with general chemotherapy drugs. The team is now keen on expanding their model to incorporate varied data types, like pathology and radiology images, to provide a more comprehensive prediction using multiple data modalities. This would also provide the model with a comprehensive perspective of tumors, allowing it to predict the tumor type as well as the most appropriate treatment.

“That was the most important finding in our paper, that this model could be potentially used to aid treatment decisions, guiding doctors toward personalized treatments for patients with cancers of unknown primary origin,” said Intae Moon, an MIT graduate student in electrical engineering and computer science who was the lead author of the new study.

Related Links:
MIT
Dana-Farber Cancer Institute 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Immunofluorescence Analyzer
MPQuanti
New
Multi-Function Pipetting Platform
apricot PP5

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.